165,000 dementia patients reveal hidden stroke risk from common drug
Why it matters: A common dementia drug may be silently raising stroke risk for millions of vulnerable patients.
- Brunel University of London led the massive observational study that linked risperidone to higher stroke incidence in dementia patients.
- British Journal of Psychiatry published the findings, underscoring the uniform risk across patient sub‑groups.
- Risperidone is the sole drug of its class approved for dementia agitation, yet the study shows no clearly safe patient profile.
- Clinicians must now weigh the drug’s agitation‑calming benefits against a newly confirmed stroke hazard.
- Regulators may need to issue dementia‑specific monitoring guidelines, as current practice lacks clear safety protocols.
A UK cohort of 165,000 dementia patients reveals that risperidone—the only antipsychotic licensed for dementia—elevates stroke risk across all groups, even those without prior heart disease, shattering the idea of any “safe” sub‑population and sparking calls for tighter prescribing and monitoring.
